Search | Clinical Trials Finder

Conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Leukemia
Interventions: Azacitidine, Ara-C; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Pomalidomide, Dexamethasone, Nivolumab; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 22
States / cities: Mobile, Alabama • Santa Barbara, California • Denver, Colorado + 17 more

Conditions: Erectile Dysfunction
Interventions: MoreNova; Device
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years to 55 Years · Male only
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Central Neuropathic Pain, Allodynia, Spinal Cord Injury
Interventions: Dextromethorphan, Lidocaine, Placebo (Dextromethorphan), Placebo (Lidocaine); Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 70 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Asthma
Interventions: House Dust Mite SLIT, High dose SLIT, Placebo SLIT; Biological
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 50 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Colic
Interventions: Nepadutant; Drug
Lead sponsor: Menarini Group; Industry
Eligibility: Up to 6 Months
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 5
States / cities: Little Rock, Arkansas • Atlanta, Georgia • Louisville, Kentucky + 2 more

Conditions: Dystocia
Interventions: Oxytocin, Sodium Chloride 0.9%; Drug · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 1,003 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Safety of Short Term Creatine Hydrochloride Dosing
Interventions: creatine supplementation; Dietary Supplement
Lead sponsor: Vireo Systems, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Raritan, New Jersey

Conditions: Gastric Ulcer, Duodenal Ulcer
Interventions: Esomeprazole 40 mg, Esomeprazole 20 mg, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years and older
Enrollment: 2,426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 55
States / cities: Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 52 more

Conditions: DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma, Mediastinal Large B-cell Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma
Interventions: Bridging radiation therapy, Liso-cel, Post-infusion radiation; Radiation · Biological
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Sleep Apnea
Interventions: Acetazolamide; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 80 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Hypothalamic Obesity
Interventions: Placebo, Tesomet; Other · Drug
Lead sponsor: Saniona; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Lansing, Michigan

Conditions: Advanced Melanoma, Stage III and IV Melanoma
Interventions: Biological: MKC1106-MT, Biological: MKCC1106-MT; Biological
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 2
States / cities: Los Angeles, California • Tampa, Florida

Conditions: Huntington's Disease
Interventions: OMS643762, Placebo; Drug
Lead sponsor: Omeros Corporation; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 9
States / cities: San Diego, California • Englewood, Colorado • Gainesville, Florida + 6 more

Conditions: Myelokathexis, Infections, Neutropenia, Warts, Hypogammaglobulinemia
Interventions: Plerixafor, G-CSF; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 10 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pain
Interventions: 440 mg naproxen sodium with 1000 mg acetaminophen, 220 mg naproxen sodium with 650 mg acetaminophen, 10 mg hydrocodone + 650 mg acetaminophen, 440 mg naproxen sodium, Placebo tablet; Drug
Lead sponsor: Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division; Industry
Eligibility: 17 Years to 50 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Shigellosis
Interventions: Shigella 4V, MenACWY, Rabies, Diphtheria, Tetanus and Pertussis (DTaP), Placebo; Biological
Lead sponsor: LimmaTech Biologics AG; Industry
Eligibility: 8 Months to 50 Years
Enrollment: 597 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 0
States / cities: Not listed

Conditions: Intermittent Claudication, Peripheral Artery Disease
Interventions: PLX-PAD Low dose, PLX-PAD high doses, Double Placebo, high dose +Placebo; Biological
Lead sponsor: Pluristem Ltd.; Industry
Eligibility: 45 Years to 85 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 15
States / cities: Birmingham, Alabama • Clearwater, Florida • Gainesville, Florida + 12 more

Conditions: Traumatic Brain Injury, Acute Brain Injuries
Interventions: gammaCore active device, gammaCore sham device; Device
Lead sponsor: CentraCare; Other
Eligibility: 18 Years to 60 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Neurodermatitis
Interventions: Dupilumab SAR231893, Placebo, Moisturizers, Low to medium potent topical corticosteroids, Topical calcineurin inhibitors; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 21
States / cities: Gilbert, Arizona • Fort Smith, Arkansas • Sacramento, California + 18 more

Conditions: Mantle-Cell Lymphoma
Interventions: Ibrutinib, Venetoclax, Placebo Oral tablet to match Venetoclax; Drug
Lead sponsor: Pharmacyclics LLC.; Industry
Eligibility: 18 Years and older
Enrollment: 366 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 14
States / cities: Tucson, Arizona • Duarte, California • Los Angeles, California + 10 more

Conditions: Hookworm Infection, Hookworm Disease
Interventions: Na-GST-1/Alhydrogel®, CpG 10104; Biological
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 18 Years to 50 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Respiratory Syncytial Virus Infections
Interventions: JNJ-53718678, Placebo; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 28 Days to 3 Years
Enrollment: 246 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 14
States / cities: Madera, California • Ventura, California • Aurora, Colorado + 11 more

Conditions: Sickle Cell Disease, Sickle Cell Anemia, Stroke, Ischemic, Silent Stroke, Silent Cerebral Infarct, Stroke
Interventions: Hydroxyurea therapy per standard care; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 16 Years to 26 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Nashville, Tennessee

Search by objective public record fields.

Phase I/II Study of 5-Azacytidine With Ara-C in Patients With Relapsed/Refractory Acute Myelogenous Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.

Low Intensity Shock Wave Therapy in the Management of Erectile Dysfunction

Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination Clinical Trial

Immunotherapy Administered Under the Tongue to Treat Dust Mite Allergy

Preliminary Efficacy, Safety and Pharmacokinetics Study of Nepadutant in Infant With Feeding Intolerance

Comparison of Low-dose and High-dose Oxytocin Regimens for Labor Augmentation

Short-Term Safety of Low-Dose Creatine Hydrochloride: A 28-Day Single-Arm Pilot Study

Study of Esomeprazole 20 mg or 40 mg vs Placebo Effectiveness on the Occurrence of Peptic Ulcers in Subjects on Low Dose Acetylsalicylic Acid (LDA)

Low Dose Radiation as Bridging Therapy in Relapsed B-Cell Non-Hodgkin Lymphoma

A Single-center Pilot Study Evaluating the Immediate Effects of Low-dose Acetazolamide on Respiratory Control in Subjects With Treatment Emergent Sleep Disordered Breathing

Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO)

Safety and Immune Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma.

Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease

Plerixafor Versus G-CSF in the Treatment of People With WHIM Syndrome

Naproxen Sodium/Acetaminophen Proof of Concept Dosing Study

A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants

Safety and Efficacy of Allogeneic Cells for the Treatment of Intermittent Claudication(IC)

Vagus Nerve Stimulation to Treat Moderate Traumatic Brain Injury

Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (LIBERTY-PN PRIME)

Study of Ibrutinib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (MCL)

Safety and Immunogenicity Study of Na-GST-1 With or Without CpG

Study to Evaluate Safety and Antiviral Activity of Doses of JNJ-53718678 in Children (>=28 Days to <=3 Years) With Respiratory Syncytial Virus Infection

Stroke Prevention in Young Adults With Sickle Cell Anemia